title: TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
abstract: The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer. Gene copy number of TOP2A and HER2 were analysed with chromogenic in situ hybridization (CISH) on paraffin-embedded tissue sections from the primary tumour of 85 patients treated with anthracycline containing chemotherapy. TOP2A gene amplification was present in 14 (16%) and HER2 gene amplification in 38 (45%) of the primary tumours. Two of the 14 cases with TOP2A amplification were amplified without concurrent HER2 amplification. Neither TOP2A nor HER2 gene amplification were significantly associated with response to chemotherapy (p = 0.35 and p = 0.49, respectively).
authors.affiliation: Department of Oncology, Orebro University Hospital, Sweden. kenneth.villman@orebroll.se
authors.forename: Kenneth
authors.initials: K
authors.lastname: Villman
authors.forename: Johanna
authors.initials: J
authors.lastname: Sjöström
authors.forename: Reino
authors.initials: R
authors.lastname: Heikkilä
authors.forename: Ragnar
authors.initials: R
authors.lastname: Hultborn
authors.forename: Per
authors.initials: P
authors.lastname: Malmström
authors.forename: Nils-Olof
authors.initials: NO
authors.lastname: Bengtsson
authors.forename: Martin
authors.initials: M
authors.lastname: Söderberg
authors.forename: Eero
authors.initials: E
authors.lastname: Saksela
authors.forename: Carl
authors.initials: C
authors.lastname: Blomqvist
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D002863:Chromogenic Compounds; D004250:DNA Topoisomerases, Type II / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D018450:Disease Progression; D005260:Female; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization; D008875:Middle Aged; D000075223:Poly-ADP-Ribose Binding Proteins; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D046888:Tissue Array Analysis / Q000379:methods; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002863:Chromogenic Compounds; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human